Ascendis Pharma A/S (ASND) Q3 2024 Earnings Conference Call November 14, 2024 4:30 PM ET

Company Participants

Jan Mikkelsen - President & Chief Executive Officer
Scott Smith - Executive Vice President & Chief Financial Officer
Camilla Harder Hartvig - Head of Global Commercial Operation
Joe Kelly - US General Manager

Conference Call Participants

Jessica Fye - JPMorgan
Tazeen Ahmad - Bank of America
Yaron Werber - TD Cowen
Gavin Clark-Gartner - Evercore ISI
Li Watsek - Cantor Fitzgerald
Joseph Schwartz - Leerink Partners
Vikram Purohit - Morgan Stanley
Kelly Shi - Jefferies
David Lebowitz - Citigroup Inc.
Paul Choi - Goldman Sachs
Leland Gershell - Oppenheimer
Alexander Thompson - Stifel

Operator

Good day, and thank you for standing by. Welcome to the Ascendis Pharma Third Quarter Earnings Call. At this time all participants are in a listen-only mode. After the speaker's presentation, there will be a question-and-answer session. [Operator Instructions] Please be advised that today's conference is being recorded.

I would now like to turn the conference over to your speaker for today, Scott Smith, Chief Financial Officer. Please go ahead.

Scott Smith

Thanks so much, operator, and thank you, everyone, for joining our Third Quarter 2024 Financial Results Conference Call. I'm Scott Smith, Executive Vice President and Chief Financial Officer at Ascendis Pharma. I'm joined today by Jan Mikkelsen, President and Chief Executive Officer.

Before we begin, I would like to remind you that this conference call will contain forward-looking statements that are intended to be covered under the safe harbor provided by the Private Securities Litigation Reform Act. Examples of such statements may include, but are not limited to, statements regarding our commercialization and continued development of SKYTROFA and YORVIPATH for the US. and European markets, as well as certain financial expectations, our pipeline candidates and our expectations with respect to their continued progress and potential commercialization, our strategic plans and partnerships, our goals regarding our clinical pipeline, including the timing of clinical results and trials, our ongoing and planned regulatory filings and our expectations regarding the timing and the results of regulatory decisions, expected market developments and our exploration of market opportunities in the therapeutic areas of endocrinology rare disease.

These statements are based on information that is available to us as of today. Actual results may differ -- could differ materially from those in our forward-looking statements, and you should not place undue reliance on these statements. We assume no obligation to update these statements as circumstances change, except as required by law. For additional information concerning the factors that could cause actual results to differ materially, please see our forward-looking statements section of today's press release and the Risk Factors section of our prospectus supplement filed on September 20, 2024, and our most recent annual report on Form 20-F filed with the SEC on February 7, 2024.